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T R A N S F U S I O N  P R A C T I C E
 
Use of B-natriuretic peptide as a diagnostic marker 
in the differential diagnosis of transfusion-associated 
circulatory overload
 




 Transfusion-associated circulatory 
overload (TACO) occurs when the transfusion rate or 
volume exceeds the capacity of a compromised 
cardiovascular system. Characteristic symptoms and 
signs associated with TACO are neither sensitive nor 
specific. B-natriuretic peptide (BNP) is a 32-amino-acid 
polypeptide secreted from the cardiac ventricles in 
response to ventricular volume expansion and pressure 
overload. This study was performed to explore the usage 
of BNP in the differential diagnosis of TACO.
 
STUDY DESIGN AND METHODS:
 
 Pre- and posttrans-
fusion BNP levels were determined in 21 patients with 
suspected TACO and 19 control patients. The BNP 
was considered significant if the posttransfusion-to-
pretransfusion ratio was at least 1.5 and the posttransfu-




 The BNP test has a sensitivity and specificity 
of 81 and 89 percent, respectively, in diagnosis of TACO. 
It has a positive predictive value of 89 percent, a negative 
predictive value of 81 percent, and an accuracy of 
87 percent. In logistic regression analysis, BNP was 
found to have significant predictive power independent of 





 Our study suggests that in patients who 
present symptoms suggestive of TACO, BNP can be a 
useful adjunct marker in confirming volume overload as 
the cause of acute dyspnea and symptoms related to 
cardiovascular compromise.
 
cute respiratory distress during or shortly
after transfusion may be due to transfusion-
associated circulatory overload (TACO),
transfusion-related acute lung injury (TRALI),
allergic reactions, or underlying disease. The risk of TACO
is generally believed low; however, the incidence can be as




The risk factors associated with TACO include an impaired
cardiovascular system, renal insufficiency, and anemia
with expanded plasma volumes. Elderly people and
infants are especially susceptible to TACO.
Because fluid overload increases central venous pres-
sure, resulting in pulmonary edema, TACO can present
as dyspnea, tachypnea, tachycardia, acute hypertension,
jugular venous distension, S3, and pulmonary rales. In
severe cases, cardiomegaly and pulmonary edema can be
seen on chest X-ray (CXR). These manifestations and CXR
findings, however, are not specific for TACO and some may
be observed in TRALI, febrile nonhemolytic transfusion
reactions (FNHTRs), and allergic reactions. Most FNHTRs
and allergic reactions can be readily differentiated from
TACO. It could be difficult in some cases, however, to
exclude other reactions and confirm TACO as the under-
lying cause of transfusion-associated acute respiratory
distress. It is essential to exclude TRALI as causes of respi-
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ratory distress and pulmonary edema in the setting of





tral venous and pulmonary wedge pressures are elevated
in patients with TACO but should be normal in TRALI;
however, these measurements are invasive and not con-
sistently diagnostic and are not always readily available.
Therefore, there is at present no easy-to-perform diagnos-
tic test in the differential diagnosis of acute respiratory
distress in the setting of transfusion.
Because TACO causes volume expansion in the car-
diovascular system including the ventricular compart-
ment, we sought to determine whether the measurement
of the brain-type natriuretic peptide (BNP) could be used
as an adjunct test in the differential diagnosis of transfu-
sion-related acute respiratory distress or change of vital
signs. BNP is a 32-amino-acid polypeptide secreted from
the cardiac ventricles in response to ventricular pressure




 BNP promotes natri-
uresis and diuresis, acts as a vasodilator, and counteracts





shown that plasma BNP concentrations increase in
patients with systolic dysfunction, diastolic dysfunction,





clinical trials have demonstrated the usefulness of BNP as
a diagnostic marker of heart failure in patients presenting









80 pg/mL) can rapidly rule out
decompensated heart failure, whereas high BNP values
can confirm a diagnosis of heart failure. Furthermore,
plasma BNP concentrations have been shown to yield
prognostic information that supplements conventional
clinical, biochemical, neurohormonal, invasive, and non-
invasive evaluations in patients with chronic heart failure




In this study, we tested whole-blood BNP levels by a
rapid immunoassay in patients who presented with short-
ness of breath or other symptoms and signs suggestive of
TACO during or shortly after receiving transfusion. We
sought to determine whether BNP testing could serve as a
useful aid in the differential diagnosis of acute respiratory







This study was approved by the University of Michigan
Institutional Review Board and conducted at the Univer-
sity of Michigan Hospital between September 2003 and
June 2004. Forty patients were included in the study.
Among these 40 patients, 21 initially presented symptoms
and signs of acute respiratory distress and/or acute hyper-
tension and tachycardia associated with transfusions dur-
ing the study period and were diagnosed with TACO. This
number represented an incidence of TACO of 0.025
percent of all blood components transfused and 10
percent of all reported transfusion reactions during
the study period. We randomly selected an additional 19
patients who received transfusions during the study
period as controls. These 19 cases included 6 patients with
FNHTRs, 3 patients with allergic reactions, and 10 patients
without reactions (52.6%).
 
Laboratory evaluation of transfusion reactions
 
A blood sample collected in tubes containing ethylenedi-
aminetetraacetate (EDTA) was requested when a transfu-
sion reaction was reported to the blood bank (usually
within 2 hr after the transfusion was stopped). Clerical
checks, visual checks for hemolysis, and direct antiglobu-
lin tests were performed by blood bank technologists as
the initial work-up on both posttransfusion and pretrans-
fusion samples. In addition, the patient’s ABO type was
reconfirmed. The transfusion reaction was then signed
out by the blood bank resident and the blood bank attend-
ing physician based on these test results and a careful
review of the patient’s symptoms and signs, CXR findings,
and pertinent clinical history (e.g., patient’s fluid balance
8 and/or 24 hr before transfusion, microbiologic studies,
cardiac status, respiratory status). TACO was diagnosed
based on the patient’s respiratory symptoms, central
venous or pulmonary wedge pressure (when available),
arterial oxygen saturation, physical findings such as jugu-
lar venous distension and pulmonary rales, and related
medical information such as positive fluid balance before
transfusion, pulmonary edema or cardiomegaly on CXR,
and improvement of dyspnea in response to diuresis.
TRALI was excluded in all cases after careful assessment
including an extensive review of the patient’s clinical his-
tory and presentation and laboratory studies based on the
consensus definition of TRALI during or within 6 hr of
transfusion not temporally related to a competing etiology




 We also compared posttransfusion
and pretransfusion white blood  cell counts, if available, in






Blood samples collected in tubes containing EDTA for lab-
oratory transfusion reaction investigations were used for
quantitative determination of BNP. Whole-blood BNP
levels were measured by use of a BNP test (Triage, Biosite
Inc., San Diego, CA). The Triage BNP test is a fluorescent
immunoassay for whole-blood and plasma BNP level
determination. The technologist who performed the BNP
testing was blinded to the type of reaction the patient had
experienced. The BNP level from a pretransfusion sample
from the patient (usually a type-and-screen sample) was











C once received. In most of the cases, BNP tests
were performed immediately after samples were col-
lected. Pretransfusion samples and a few posttransfusion
samples were stored up to 72 hours before BNP tests were
performed. A BNP ratio from the posttransfusion sample





The study was designed as a nested case control study.





 SD values or medians as appropriate. Univariate
comparisons were made with Fisher’s exact test or a t test
for paired data as appropriate. We constructed receiver-
operating-characteristic curves to evaluate various cutoff
values for BNP. We selected the posttransfusion-to-pre-
transfusion BNP ratio of 1.5 as the cut point for a positive
test on the receiver-operating-characteristic curve that
maximized both sensitivity and specificity. In addition, for
a BNP level to be determined as positive, the posttransfu-





computer software (KaleidaGraph, Sydney Software,
Fugerson, MO) to draw the box-and-whisker plot. Finally,
we used a multiple logistic regression model (SPSS, Ver-
sion 12.0, SPSS Inc., Chicago, IL) combining clinical find-
ings and BNP values to predict the final diagnosis. All
independent variables in a block were entered in a single
step as in a “simultaneous” method. The success of this







The characteristics of the 40 patients are shown in Table 1.
Patients were divided into two groups on the basis of diag-
nosis. Twenty-one of 40 patients were diagnosed as having
TACO according to the criteria used under Materials and
Methods, whereas the control group was composed of




 10), as well as
patients with FNHTR and allergic reactions. Male and
female subjects were equally distributed in both groups.
Among those patients who were diagnosed with TACO,
33.3 percent had hypertension, 9.5 percent had history of
diabetes mellitus, 14.3 percent had coronary artery dis-
ease, 33.3 percent had congestive heart failure (CHF), and
33.3 percent had impaired renal function. The percentage
of patients with TACO who had CHF or hypertension was
not different from the control group. More patients in the
control group had diabetes and coronary artery disease
(21.1 and 26.3%, respectively), whereas fewer patients in
the control group had impaired renal function (21.1% in
the control group vs. 33.3% in patients with TACO).
 
Stability of BNP during storage and their levels in 
TACO and controls
 
The measurable range of the BNP assay was 5.0 to
5000.0 pg per mL. The coefficient of variation for interas-
say precision is determined to be 9.9, 12.0, and
12.2 percent for BNP levels of 71, 630, and 4100 pg per mL,
respectively. The standard deviation is 7.0, 69, and
475.5 pg per mL for the aforementioned three BNP levels,
respectively. Because posttransfusion BNP levels were
compared to those of pretransfusion samples that could
be stored for up to 3 days, the stability of BNP in the EDTA-
anticoagulated tube was determined. Whole-blood BNP









 We found that the whole-










Figure 1 presents a box plot of both pre- and post-
transfusion BNP values for the two groups of patients.
Patients with TACO had median pretransfusion BNP levels
of 216 pg per mL. The median posttransfusion levels were
389 pg per mL. The mean difference between posttransfu-





paired t test). Patients in the control group had a median
pretransfusion BNP level of 181 pg per mL and a median
posttransfusion BNP level of 124 pg per mL, respectively.
The mean difference between posttransfusion and pre-




 0.49 by paired t test).
Because significant variation between patients was
observed for BNP levels in both groups, the BNP ratio of
after transfusion to before transfusion was used to com-
pare between the study group and the control group. The
median posttransfusion-to-pretransfusion BNP ratio was
2.1 in patients with TACO and 1.0 in the control group
(Fig. 2). The difference between groups was significant for














paired t tests. Because the control group is composed of
a mixture of patients with no transfusion reactions,
FNHTRs, and allergic reactions, we also compared BNP
 






















Sex (male/female) 10/11 10/9
Hypertension 7 (33.3) 7 (36.8)
Diabetes mellitus 2 (9.5) 4 (21.1)
Coronary artery disease 3 (14.3) 6 (26.3)
CHF 7 (33.3) 7 (36.8)
Impaired renal function 7 (33.3) 4 (21.1)
* Data are reported as number (%). Hypertension, diabetes 
mellitus, coronary artery disease, CHF, and impaired renal 
function are defined based on patients’ medical notes.
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levels only in patients who had no transfusion reactions.
The pre- and posttransfusion median levels of BNP were
228 and 157 pg per mL, respectively, and the median BNP
ratio was 0.9. The mean difference between post- and pre-




 0.37 by paired t test).
The p value for the difference of BNP ratio between those
10 patients and patients with TACO was 0.093, whereas the
p values between these two groups for the difference of
pretransfusion BNP levels and posttransfusion BNP levels
were 0.74 and 0.20, respectively.
Figure 3 shows plots of posttransfusion BNP levels
against pretransfusion BNP levels in individual patients.
Although a linear relationship was observed in both
groups, there were distinct differences in kinetics. In










). There was one outlier in the control group that
did not fit with all the other data points (indicated by the
open circle in Fig. 3A). This patient had a history of CHF






Box-and-whisker plot of BNP levels in pretransfusion 
and posttransfusion whole-blood samples in patients with 
TACO and patients with other transfusion reactions (control). 
The horizontal line indicates the median; the box limits indi-
cate the first and the third quartile. Open circles indicate outli-
ers. Some of the outliers in TACO and control patients were not 
shown. Detailed pre- and posttransfusion BNP levels in each 










Box-and-whisker plots of the ratio of the posttransfu-
sion-to-pretransfusion BNP levels for patients with TACO and 
patients with other transfusion reactions (control). The hori-
zontal line indicates the median; the box limits indicate the first 
and the third quartile. The lines extending from the top and 
bottom of each box mark the minimum and maximum values 











(B) or controls (A). The open 
circle in A indicates the data point that does not fit with the rest of the data. The relation between post- and pretransfusion BNP levels 
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fusions. His pre- and posttransfusion BNP levels were
both significantly elevated, but did not have any respira-
tory symptoms or significant change of blood pressure or
posttransfusion tachycardia. It is unclear whether his ele-
vated posttransfusion BNP level was caused by fluid over-
load or due to deterioration of his heart failure.
Figure 4 shows the receiver-operating-characteristic
curve for various cutoff levels of posttransfusion-to-
pretransfusion BNP ratios in differentiating TACO from





 0.05. A BNP ratio of 1.5 was
selected as the cut point for our study. It
had a sensitivity of 81 percent, a speci-
ficity of 89 percent, a positive predictive
value of 89 percent, a negative predictive
value of 81 percent, and an accuracy of
87 percent. Lower values such as a ratio of
0.7 were associated with greater negative
predictive values (92%).
 
Comparison of BNP and clinical risk 
factors in TACO
 
Clinical data were reviewed for all patients
included in this study (Table 2). Only
acute dyspnea, posttransfusion systolic
hypertension (increase of systolic blood
pressure by greater than 30 mmHg), and
elevated BNP levels were different
between the TACO patients and the con-
trol group. Tachycardia or significant
change in heart rate (increase of heart rate
greater than 20/min) after transfusion,
multiple blood product transfusion, his-
tory of CHF, and impaired renal function
were not significantly different between
the two groups by Fisher’s exact test.
Multivariate logistic regression was
used to compare the ability of BNP and
other clinical factors to predict TACO
(Table 3). The independent variables used




65 years), male sex, his-
tory of CHF, renal function impairment, transfusion of
multiple blood products, acute dyspnea during or shortly
after transfusion, systolic hypertension, significant
change in heart rate during or shortly after transfusion,
and a positive BNP test. Based on the results shown in
Figs. 3 and 4, a positive BNP test was defined as a post-
transfusion-to-pretransfusion BNP ratio equal to or






Receiver-operating-characteristic curve for various cutoff levels of BNP in 
diagnosis of TACO.
 












 19) P value
Acute dyspnea 13 (61.9) 2† (10.5) 0.0002




20 beats/min) 6 (28.6) 5 (26.3) 1.0
Significant change in systolic blood pressure after





12 (57.1) 2 (10.5) 0.003
Transfusion of multiple units 16 (76.2) 11 (57.9) 0.31
History of CHF 7 (33.3) 7 (36.8) 1.0
Impaired renal function 7 (33.3) 3 (15.8) 0.28















* Data are reported as number (%).
† Including one patient who presented acute dyspnea with an underlying diagnosis of pneumonia.
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 The presence of TACO was
the dependent variable. Only a positive BNP test and sys-
tolic hypertension contributed significantly to the identi-









At present, BNP is probably best used as a diagnostic tool





 We have shown in this study the applica-
tion of BNP as a diagnostic adjunct test in confirming
TACO as the cause of acute dyspnea and symptoms
related to cardiovascular compromise.
In our study, we determined the pretransfusion, post-
transfusion, and post- and pretransfusion BNP levels in
patients with a diagnosis of TACO compared to a control
group of patients who received transfusions. Among con-
trol patients who received transfusions, there was little or
no increase in BNP levels after transfusion (BNP ratio, 1.0),
suggesting that routine transfusion has minimal effect on
whole-blood BNP levels, even in the presence of febrile
and allergic reactions, which are frequently encountered
in patients receiving transfusions. This was also true in a
subanalysis of transfused patients without transfusion
reactions (BNP ratio, 0.9), which represented 52.6 percent
of all controls. In contrast, the median pre- and posttrans-
fusion BNP levels and BNP ratio were all significantly
increased among TACO patients. Our results suggest that
BNP may be a useful diagnostic test for differentiating
TACO from other transfusion reactions in patients pre-
senting transfusion-associated respiratory distress or
change of vital signs. Because of the wide range of baseline
BNP levels observed in some patients in both study and
control groups, we believe that the post- and pretransfu-
sion BNP ratio more accurately reflects the intravascular
response to transfusion, particularly in the presence of
confounding clinical conditions (CHF, renal failure) which
were present in one-third of all subjects.
Consistent with the other two large studies in which
it was concluded that BNP levels by themselves were more
accurate than any other clinical factors (historical, physi-





 our study also suggests that the BNP level
and its kinetic changes (posttransfusion-to-pretransfu-
sion ratio) is the single most accurate predictor of the
presence or absence of TACO. The diagnostic accuracy of
BNP posttransfusion-to-pretransfusion ratio at a cutoff
value of 1.5 was 87 percent, with a sensitivity of 81 percent
and a specificity of 89 percent. In comparison, although
acute dyspnea and systolic hypertension are both closely
associated with TACO, the diagnostic accuracy was 75 and
73 percent, respectively. Furthermore, through a multi-
variate logistic regression analysis, we determined that a
BNP ratio of 1.5 (posttransfusion/pretransfusion) was the
strongest independent predictor of TACO, with an OR of
25.63.
The majority of patients with TACO can be readily
identified based on symptoms of acute dyspnea,
decreased arterial oxygen saturation, tachypnea, systolic
hypertension, or pulmonary rales in the setting of trans-
fusion. Other transfusion reactions, however, can present
overlapping symptoms and signs that can be difficult to
differentiate from TACO in some cases. An increase in
both respiratory rate and systolic blood pressure, without
a rise in temperature, has been shown to be suggestive of





 Allergic reactions and nonspecific events
unrelated to transfusion, however, may also present with
these signs. Although patients with TRALI more likely
present hypotension rather than hypertension, hypoten-
sion in response to acute volume expansion is also
observed in patients with decompensated heart failure.
Both patients with TACO and TRALI may show pulmonary
edema on CXR, making CXR less useful in the differential
diagnosis. Compared with other invasive tests such as
measuring of central venous and pulmonary wedge pres-
sure, BNP immunoassay is a rapid, point-of-care test,
whose result is readily available in 15 minutes. Therefore,
in cases where TACO and other transfusion reactions,
especially TRALI, are not easily differentiated, measuring





 We did not encounter any cases of TRALI during
the study period. Therefore, whether BNP can be used to
 
TABLE 3. Multivariate logistic regression analysis of the ability of BNP and other clinical indicators to identify TACO
 





 65 years 0.19 0.17 0.01-2.46
Male sex 0.64 0.59 0.06-5.62
History of CHF 0.92 0.88 0.08-10.19
Impaired renal function 0.55 0.45 0.03-6.03
Acute dyspnea 0.095 14.09 0.64-311.35
Transfusion of multiple units 0.24 0.26 0.03-2.44











20 beats/min) 0.48 0.43 0.04-4.47
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differentiate TACO from TRALI needs to be further
evaluated.
BNP is one of the three major natriuretic peptides, all
sharing a common 17-amino-acid ring structure: atrial (A-





 The major source of plasma BNP
is cardiac ventricles, and its release is directly proportional




BNP is a 32-amino-acid biologically active fragment
released from the BNP precursor, proBNP, which is a hor-
mone of 108 amino acids. The remaining part is a 76-




Both BNP and NT-proBNP levels have been shown to




 In patients with
left ventricular dysfunction, NT-proBNP levels rise 2 to




 Measurement of NT-proBNP
has recently become available in the clinical laboratory
(Roche Diagnostics). It remains undetermined whether
NT-proBNP is comparable with or even better than BNP
to predict TACO in the setting of transfusion. With a half-
life of 22 minutes in blood, BNP can accurately reflect pul-
monary capillary wedge pressure changes every 2 hours.
The plasma half-life of NT-proBNP, in comparison, is
much longer (120 min), suggesting that it can be used to





fore, the BNP level at the time it is drawn may be more
reflective of acute volume expansion and ventricular pres-
sure overload at that moment. Unlike BNP, which is
mainly cleared by neutroendopeptidase, NT-proBNP is
mainly cleared by the kidneys. Its level is therefore signif-
icantly influenced by renal function as well as age. Given
the differences between these two tests, we believe that
the BNP is the test of choice for transfusion reaction eval-
uation at this time.
In our study, BNP levels varied greatly among
patients (5-5000 pg/mL). Pretransfusion BNP levels were
consistently higher in patients with history of CHF and/
or impaired renal functions. To our surprise, however,
we found that neither CHF nor history of impaired renal
function is associated with or can predict TACO. This
can be partly explained by the relatively small size of
patient groups included in the study and also possibly
due to biased patient selection since CHF and impaired
renal functions are frequent in patients in a tertiary care
hospital. Among the symptoms presented with TACO,
acute dyspnea and systolic hypertension, but not tachy-
cardia, are clinical indicators of TACO. Although tachy-
cardia is frequently observed in acute volume
expansion, it is also associated with FNHTR. In addition,
our study shows that it is difficult to use multiunit trans-
fusion as a predictor of TACO, probably due to the
reason that most of the individuals in our study are
hospitalized patients with complicated medical presen-
tations that require frequent transfusion of multiple
blood products.
In conclusion, we have shown that BNP testing is a
valuable adjunct in confirming or excluding TACO as the
cause of transfusion-associated acute dyspnea or change
of vital signs. The diagnosis of TACO in most cases, how-
ever, does not require BNP testing. Complicated cases
presenting acute pulmonary symptoms in the setting
of transfusion are not infrequently seen, especially in
patients with compromised cardiopulmonary functions
and impaired renal functions. With its high sensitivity and
predictive values, the addition of BNP testing in the setting
of transfusion-associated acute respiratory distress has





 Low BNP levels can exclude TACO
whereas high BNP levels favor TACO. High BNP levels,
however, do not exclude the diagnosis of other transfusion
reactions such as TRALI or allergic reactions because
those conditions can coexist. Finally, the diagnosis of
TACO should not be based on the BNP levels alone;
instead, this information should be considered in the con-
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